Jens Gundgaard
Bagsvaerd, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden.
Journal: PharmacoEconomics
Published: September 14, 2025
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.
Journal: Alzheimer's research & therapy
Published: November 24, 2023
Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
Journal: Journal of medical economics
Published: November 12, 2021
Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 12, 2020
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Journal: Journal of medical economics
Published: August 05, 2020
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
Journal: Advances in therapy
Published: February 28, 2020
Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
Journal: Journal of medical economics
Published: September 19, 2019
What is innovation in the area of medicines? The example of insulin and diabetes.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: July 25, 2019
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Journal: Applied health economics and health policy
Published: July 03, 2019
Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.
Journal: BMJ open diabetes research & care
Published: February 08, 2019
Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Journal: Diabetes, obesity & metabolism
Published: November 16, 2018
Last Updated: 09/26/2026